Apimostinel (original) (raw)
Apimostinel (GATE-202, formerly NRX-1074) is an investigational antidepressant, acting as a novel and selective modulator of the NMDA receptor. It is currently under development for the acute treatment of major depressive disorder (MDD) by Gate Neurosciences, and previously by Naurex and Allergan. As of February 2015, an intravenous formulation of apimostinel has completed a phase IIa clinical trial for MDD.
| Property | Value |
|---|---|
| dbo:abstract | Apimostinel (GATE-202, formerly NRX-1074) is an investigational antidepressant, acting as a novel and selective modulator of the NMDA receptor. It is currently under development for the acute treatment of major depressive disorder (MDD) by Gate Neurosciences, and previously by Naurex and Allergan. As of February 2015, an intravenous formulation of apimostinel has completed a phase IIa clinical trial for MDD. Similar to rapastinel (GLYX-13), its mechanism of action acts through a unique binding site on the NMDA receptor, independent of the glycine site, to modulate receptor activity and enhance NMDAR-mediated synaptic plasticity. However, apimostinel is 1000-fold more potent in vitro and is intended as an improved, follow-up drug to rapastinel. Similar to rapastinel, apimostinel is an amidated tetrapeptide, but has been structurally modified, via the addition of a benzyl group, to enhance its metabolic stability and pharmacokinetic profile. The drug has shown rapid and potent antidepressant effects in pre-clinical models of depression. In addition, similarly to rapastinel, it is well tolerated and lacks the schizophrenia-like psychotomimetic effects of NMDA receptor antagonists such as ketamine. (en) |
| dbo:casNumber | 1421866-48-9 |
| dbo:chEMBL | 3545230 |
| dbo:fdaUniiCode | TTT1F11FZB |
| dbo:kegg | D11299 |
| dbo:pubchem | 71249967 |
| dbo:thumbnail | wiki-commons:Special:FilePath/NRX-1074.svg?width=300 |
| dbo:wikiPageExternalLink | http://adisinsight.springer.com/drugs/800038114 |
| dbo:wikiPageID | 43273034 (xsd:integer) |
| dbo:wikiPageLength | 7167 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1123675255 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Psychotomimetic dbr:Schizophrenia dbc:Tetrapeptides dbr:Depression_(mood) dbr:List_of_investigational_antidepressants dbc:Benzyl_compounds dbc:Experimental_drugs dbc:NMDA_receptor_agonists dbc:Pyrrolidines dbr:Oral_administration dbr:Receptor_modulator dbr:Animal_model dbr:Antidepressant dbr:Benzyl_group dbr:Major_depressive_disorder dbr:Clinical_trial dbr:AGN-241751 dbr:Allergan dbr:Amide dbc:Antidepressants dbc:Carboxamides dbr:Ketamine dbr:Rapastinel dbr:Mechanism_of_action dbr:Phases_of_clinical_research dbr:NMDA_receptor_antagonist dbr:NMDA_receptor dbr:Molecular_modification dbr:Intravenous dbr:Tetrapeptide dbr:Naurex |
| dbp:c | 25 (xsd:integer) |
| dbp:casNumber | 1421866 (xsd:integer) |
| dbp:chembl | 3545230 (xsd:integer) |
| dbp:chemspiderid | 52085607 (xsd:integer) |
| dbp:h | 37 (xsd:integer) |
| dbp:iupacName | -1 (xsd:integer) |
| dbp:kegg | D11299 (en) |
| dbp:legalUs | Investigational New Drug (en) |
| dbp:n | 5 (xsd:integer) |
| dbp:o | 6 (xsd:integer) |
| dbp:pubchem | 71249967 (xsd:integer) |
| dbp:routesOfAdministration | dbr:Oral_administration |
| dbp:smiles | C[C@@H][C@H]CN1CCC[C@H]1CN2CCC[C@@]2CN[C@@H]C=O (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | DVBUEXCIEIAXPM-PJUQSVSOSA-N (en) |
| dbp:synonyms | NRX-1074; AGN-241660; Threonyl-prolyl-2R--prolyl-threonine amide (en) |
| dbp:unii | TTT1F11FZB (en) |
| dbp:width | 250 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Drugbox dbt:Ionotropic_glutamate_receptor_modulators dbt:Reflist dbt:Short_description dbt:Fdacite dbt:Antidepressants |
| dcterms:subject | dbc:Tetrapeptides dbc:Benzyl_compounds dbc:Experimental_drugs dbc:NMDA_receptor_agonists dbc:Pyrrolidines dbc:Antidepressants dbc:Carboxamides |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | Apimostinel (GATE-202, formerly NRX-1074) is an investigational antidepressant, acting as a novel and selective modulator of the NMDA receptor. It is currently under development for the acute treatment of major depressive disorder (MDD) by Gate Neurosciences, and previously by Naurex and Allergan. As of February 2015, an intravenous formulation of apimostinel has completed a phase IIa clinical trial for MDD. (en) |
| rdfs:label | Apimostinel (en) |
| owl:sameAs | yago-res:Apimostinel wikidata:Apimostinel https://global.dbpedia.org/id/2Z5B6 |
| prov:wasDerivedFrom | wikipedia-en:Apimostinel?oldid=1123675255&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/NRX-1074.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Apimostinel |
| is dbo:wikiPageRedirects of | dbr:NRX-1074 dbr:C25H37N5O6 dbr:NRX_1074 |
| is dbo:wikiPageWikiLink of | dbr:Rislenemdaz dbr:List_of_investigational_antidepressants dbr:NRX-1074 dbr:Zelquistinel dbr:C25H37N5O6 dbr:Lanicemine dbr:Rapastinel dbr:NMDA_receptor dbr:NRX_1074 |
| is foaf:primaryTopic of | wikipedia-en:Apimostinel |
